52North Company Profile: Funding, Investors & Partnerships

52North

Our innovative device helps to rapidly identify chemotherapy patients who are at risk of a life threatening complication called neutropenic sepsis. Neutropenic sepsis prematurely takes tens of thousands of lives each year and costs healthcare systems tens of billions of dollars. Through better triaging, Neutrocheck has the potential to save thousands of lives, free up valuable healthcare resources, and make patients' lives easier, simpler, and better.Our innovative device helps to rapidly identify chemotherapy patients who are at risk of a life thre Show More

Alpha Score

52.5

Total Funding$ 13.05 M